Literature DB >> 21295813

Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery.

Rajiv Kumar1, John C Lieske, Maria L Collazo-Clavell, Michael G Sarr, Ellen R Olson, Terri J Vrtiska, Eric J Bergstralh, Xujian Li.   

Abstract

BACKGROUND: Hyperoxaluria and increased calcium oxalate stone formation occur after Roux-en-Y gastric bypass (RYGB) surgery for morbid obesity. The etiology of this hyperoxaluria is unknown. We hypothesized that after bariatric surgery, intestinal hyperabsorption of oxalate contributes to increases in plasma oxalate and urinary calcium oxalate supersaturation.
METHODS: We prospectively examined oxalate metabolism in 11 morbidly obese subjects before and 6 and 12 months after RYGB (n = 9) and biliopancreatic diversion-duodenal switch (BPD-DS) (n = 2). We measured 24-hour urinary supersaturations for calcium oxalate, apatite, brushite, uric acid, and sodium urate; fasting plasma oxalate; 72-hour fecal fat; and increases in urine oxalate following an oral oxalate load.
RESULTS: Six and 12 months after RYGB, plasma oxalate and urine calcium oxalate supersaturation increased significantly compared with similar measurements obtained before surgery (all P ≤ .02). Fecal fat excretion at 6 and 12 months was increased (P = .026 and .055, 0 vs 6 and 12 months). An increase in urine oxalate excretion after an oral dose of oxalate was observed at 6 and 12 months (all P ≤ .02). Therefore, after bariatric surgery, increases in fecal fat excretion, urinary oxalate excretion after an oral oxalate load, plasma oxalate, and urinary calcium oxalate supersaturation values were observed.
CONCLUSION: Enteric hyperoxaluria is often present in patients after the operations of RYGB and BPD-DS that utilize an element of intestinal malabsorption as a mechanism for weight loss.
Copyright © 2011 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21295813      PMCID: PMC3078956          DOI: 10.1016/j.surg.2010.11.015

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  36 in total

1.  Hyperoxaluria is a long-term consequence of Roux-en-Y Gastric bypass: a 2-year prospective longitudinal study.

Authors:  Branden G Duffey; Shaheen Alanee; Renato N Pedro; Bryan Hinck; Carly Kriedberg; Sayeed Ikramuddin; Todd Kellogg; Michelle Stessman; Angela Moeding; Manoj Monga
Journal:  J Am Coll Surg       Date:  2010-07       Impact factor: 6.113

2.  Long-term mortality after gastric bypass surgery.

Authors:  Ted D Adams; Richard E Gress; Sherman C Smith; R Chad Halverson; Steven C Simper; Wayne D Rosamond; Michael J Lamonte; Antoinette M Stroup; Steven C Hunt
Journal:  N Engl J Med       Date:  2007-08-23       Impact factor: 91.245

3.  Lithogenic risk factors in the morbidly obese population.

Authors:  Branden G Duffey; Renato N Pedro; Carly Kriedberg; Derek Weiland; Jonathan Melquist; Sayeed Ikramuddin; Todd Kellogg; Antoine A Makhlouf; Manoj Monga
Journal:  J Urol       Date:  2008-03-04       Impact factor: 7.450

4.  Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative.

Authors:  Marian L Neuhouser; Lesley Tinker; Pamela A Shaw; Dale Schoeller; Sheila A Bingham; Linda Van Horn; Shirley A A Beresford; Bette Caan; Cynthia Thomson; Suzanne Satterfield; Lew Kuller; Gerardo Heiss; Ellen Smit; Gloria Sarto; Judith Ockene; Marcia L Stefanick; Annlouise Assaf; Shirley Runswick; Ross L Prentice
Journal:  Am J Epidemiol       Date:  2008-03-15       Impact factor: 4.897

5.  Bariatric surgery for morbid obesity: pre-operative assessment, surgical techniques and post-operative monitoring.

Authors:  Brane Breznikar; D Dinevski
Journal:  J Int Med Res       Date:  2009 Sep-Oct       Impact factor: 1.671

6.  Prevalence and trends in obesity among US adults, 1999-2008.

Authors:  Katherine M Flegal; Margaret D Carroll; Cynthia L Ogden; Lester R Curtin
Journal:  JAMA       Date:  2010-01-13       Impact factor: 56.272

7.  Oxalate nephropathy complicating Roux-en-Y Gastric Bypass: an underrecognized cause of irreversible renal failure.

Authors:  Samih H Nasr; Vivette D D'Agati; Samar M Said; Michael B Stokes; Maria V Largoza; Jai Radhakrishnan; Glen S Markowitz
Journal:  Clin J Am Soc Nephrol       Date:  2008-08-13       Impact factor: 8.237

8.  Gastric bypass procedures and renal calculi--how should we counsel patients and bariatric surgeons?

Authors:  John C Lieske
Journal:  J Urol       Date:  2009-09-16       Impact factor: 7.450

9.  Effect of gastric bypass surgery on kidney stone disease.

Authors:  Brian R Matlaga; Andrew D Shore; Thomas Magnuson; Jeanne M Clark; Roger Johns; Martin A Makary
Journal:  J Urol       Date:  2009-04-16       Impact factor: 7.450

10.  Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis.

Authors:  Branden G Duffey; Renato N Pedro; Antoine Makhlouf; Carly Kriedberg; Michelle Stessman; Bryan Hinck; Sayeed Ikramuddin; Todd Kellogg; Bridget Slusarek; Manoj Monga
Journal:  J Am Coll Surg       Date:  2008-04-14       Impact factor: 6.113

View more
  71 in total

1.  Obesity and Its Impact on Kidney Stone Formation.

Authors:  William Poore; Carter J Boyd; Nikhi P Singh; Kyle Wood; Barbara Gower; Dean G Assimos
Journal:  Rev Urol       Date:  2020

Review 2.  Nutritional and Micronutrient Care of Bariatric Surgery Patients: Current Evidence Update.

Authors:  Michael A Via; Jeffrey I Mechanick
Journal:  Curr Obes Rep       Date:  2017-09

Review 3.  Mechanisms underlying weight loss after bariatric surgery.

Authors:  Alexander D Miras; Carel W le Roux
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-09       Impact factor: 46.802

Review 4.  Kidney stone risk following modern bariatric surgery.

Authors:  Ricardo D Gonzalez; Benjamin K Canales
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

5.  Intestine-Specific Overexpression of LDLR Enhances Cholesterol Excretion and Induces Metabolic Changes in Male Mice.

Authors:  Luca Meoli; Danny Ben-Zvi; Courtney Panciotti; Stephanie Kvas; Palmenia Pizarro; Rodrigo Munoz; Nicholas Stylopoulos
Journal:  Endocrinology       Date:  2019-04-01       Impact factor: 4.736

Review 6.  Mechanisms of weight loss and improved metabolism following bariatric surgery.

Authors:  Christopher M Mulla; Roeland J W Middelbeek; Mary-Elizabeth Patti
Journal:  Ann N Y Acad Sci       Date:  2017-09-03       Impact factor: 5.691

7.  Steatorrhea and hyperoxaluria occur after gastric bypass surgery in obese rats regardless of dietary fat or oxalate.

Authors:  Benjamin K Canales; Joseph Ellen; Saeed R Khan; Marguerite Hatch
Journal:  J Urol       Date:  2013-03-14       Impact factor: 7.450

Review 8.  Oxalate, inflammasome, and progression of kidney disease.

Authors:  Theresa Ermer; Kai-Uwe Eckardt; Peter S Aronson; Felix Knauf
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

9.  Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery.

Authors:  Jeffrey I Mechanick; Adrienne Youdim; Daniel B Jones; W Timothy Garvey; Daniel L Hurley; M Molly McMahon; Leslie J Heinberg; Robert Kushner; Ted D Adams; Scott Shikora; John B Dixon; Stacy Brethauer
Journal:  Obesity (Silver Spring)       Date:  2013-03       Impact factor: 5.002

10.  Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient--2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery.

Authors:  Jeffrey I Mechanick; Adrienne Youdim; Daniel B Jones; W Timothy Garvey; Daniel L Hurley; M Molly McMahon; Leslie J Heinberg; Robert Kushner; Ted D Adams; Scott Shikora; John B Dixon; Stacy Brethauer
Journal:  Endocr Pract       Date:  2013 Mar-Apr       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.